Bruker Daltonics appoints Michael Schubert as executive vice president and Ian Sanders as vice president to further strengthen its senior management team
Bruker Daltonics announces two promotions to further strengthen its senior management team.
Michael Schubert has been promoted to executive vice president of the Bruker Daltonics group.
He retains his previous responsibilities for Bruker Daltonics's global R and D management, as well as his function as managing director (geschaftsfuhrer) of Bruker Daltonik, located in Bremen and Leipzig, Germany.
In addition, Schubert now also assumes responsibility for the company's life-science mass spectrometry business in the Americas.
Schubert joined Bruker Daltonics in 1991, and has held several project and R and D management positions.
In 2002, he became managing director of Bruker Daltonik, and in 2004 vice president for R and D of Bruker Daltonics.
He holds a doctorate from the University of Hamburg in physics.
Ian Sanders has been promoted to vice president for European life science sales, a function that he has previously managed as an assistant vice president.
He also continues in his role as managing director of Bruker Daltonik.
Sanders joined Bruker Daltonics in 2000 following a ten-year career in drug discovery research for both large pharmaceutical and venture biotechnology companies.
Initially responsible for the UK business, in 2002 his role expanded to manage life-science sales in the UK, Scandinavia and the Netherlands.
In 2004, he became assistant vice president for European life-science sales and, in 2005, managing director of Bruker Daltonik.
He holds a PhD in drug discovery technology from the University of Bath, UK.
Frank Laukien, president and CEO of Bruker BioSciences, said: "I am very pleased for Michael and Ian to assume additional management responsibilities at Bruker Daltonics.
"Both of them have excellent track records and I expect that in their expanded roles they will contribute even more strongly to our corporate goals.
"By focusing on customers, on technological and business innovation, and on operational excellence we drive to continue our above industry-standard revenue growth while reaching substantial profitability.
